肺动脉高压药物及新靶点研究进展

肺动脉高压（PAH）为一种少见的慢性疾病，其危害性大、致死率高，多发于老年人和妇女。随着我国步入老龄化社会，对PAH的防治越发重视。综述了包括CCBs、PDE-5抑制剂、ERAs和PGI2类常规靶点和鸟苷酸环化酶激动剂，5-羟色胺，Bcr-Abl蛋白络氨酸激酶抑制剂，Rho-激酶抑制剂，内皮祖细胞和基因等治疗该疾病的新型作用靶点在内的最新靶点与药物的研究进展，以及新一代药物的发展方向。

Research progress in drugs and new targets for treating pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a rare chronic disease with severe harm and a high mortality, and happens mainly in the elderly and women. Currently, as China is entering the aging society, more and more researches put the emphasis on the treatments of PAH. In this paper, it reviews the advanced development about new targets and drugs for treating this disease, such as calcium channel blockers (CCBs), phosphodiesterase-5 (PDE-5) inhibitors, endothelin receptor antagonist (ERAs), and prostacyclin (PGI2), and new target consisting of guanylyl cyclase agonist, serotonin, Bcr-Abl protein tyrosine kinase inhibitors, Rho-kinase inhibitors, endothelial progenitors, and genes. In addition, it also introduces the direction of the new generation of drugs in the future.